Equities

Vycor Medical Inc

VYCO:QBB

Vycor Medical Inc

Actions
  • Price (USD)0.079
  • Today's Change0.00 / 0.00%
  • Shares traded37.76k
  • 1 Year change--
  • Beta0.4726
Data delayed at least 15 minutes, as of Sep 18 2024 19:37 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Vycor Medical Inc grew revenues 19.43% from 1.22m to 1.46m while net income improved from a loss of 404.92k to a smaller loss of 69.69k.
Gross margin89.23%
Net profit margin-13.38%
Operating margin-6.09%
Return on assets-19.13%
Return on equity--
Return on investment--
More ▼

Cash flow in USDView more

In 2023, Vycor Medical Inc increased its cash reserves by 54.67%, or 20.25k. The company earned 29.43k from its operations for a Cash Flow Margin of 2.01%. In addition the company generated 210.00 cash from financing while 9.39k was spent on investing.
Cash flow per share-0.0136
Price/Cash flow per share--
Book value per share-0.1081
Tangible book value per share-0.1081
More ▼

Balance sheet in USDView more

Vycor Medical Inc uses little or no debt in its capital structure.
Current ratio0.1494
Quick ratio0.0987
Total debt/total equity--
Total debt/total capital--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.